Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis

Recent studies employing next generation sequencing (NGS) technologies have identified novel recurring mutations in monoclonal B-cell lymphocytosis (cMBL) and chronic lymphocytic leukemia (CLL).[1][1] NOTCH1 and SF3B1 mutations are the most prevalent and are associated with reduced survival